Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer (Q38186459)

30 August 2017

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer (English)

1 reference

30 August 2017

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Yan V Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1

Carol Aghajanian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Lawrence R Nycum

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Amreen Husain

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Stephanie Blank

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

6 February 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

105-110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Clinical trials in ovarian carcinoma: study methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Recommendations for the assessment of progression in randomised cancer treatment trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Analysis of interobserver and intraobserver variability in CT tumor measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Interobserver variability in the radiological assessment of response to chemotherapy in glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Blinded independent central review of the progression-free survival endpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Lessons learned from independent central review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

An audit strategy for progression-free survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.003

10.1016/J.YGYNO.2014.02.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508841%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference